Violet Therapeutics Analysis: $11M Raised
What is Violet Therapeutics?
Violet Therapeutics develops EphB3 inhibitors targeting neuroinflammation to address neurodegenerative diseases such as Alzheimer’s and Parkinson’s. Their proprietary C-to-C Engine identifies critical cell-to-cell interactions in the central nervous system. The lead program focuses on a small molecule inhibitor of EphB3, a receptor involved in glial dysfunction.
Location
Cambridge, Massachusetts 02139, United States
Employees
1-10
Founded
2021
Funding Status
Seed
Product Features & Capabilities
- EphB3 small molecule inhibitor
- C-to-C Engine for cell interaction identification
Use Cases
Targeting neuroinflammation in Alzheimer’s disease; Addressing glial dysfunction in Parkinson’s disease; Developing therapeutics for central nervous system disorders; Investigating microglia-astrocyte interactions; Advancing neurodegenerative disease treatment options
See something that needs updating? Suggest edits to this profile.